The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: CRTH 2 mediates activation of Th2 cells, eosinophils and basophils in response to prostaglandin D 2. The CRTH 2 antagonist OC 000459 has previously been demonstrated to reduce airway inflammation and improve lung function in moderate persistent asthma. The objective of the present study was to determine the involvement of CRTH 2 in promoting nasal and ocular symptoms in allergic subjects exposed to grass pollen. Methods: A single centre, randomised, double‐blind, placebo‐controlled, two‐way crossover study was conducted in 35 male subjects allergic to grass pollen comparing OC 000459 200 mg bid with placebo for 8 days. Subjects were exposed to grass pollen (≥1400 grains/m 3) for 6 h on the 2nd and 8th days of treatment and assessed for nasal symptoms, ocular symptoms, other symptoms, nasal secretion weight and rhinomanometry over the 6‐h period. After a washout period of 3 weeks, subjects were switched to the alternative treatment for a further 8 days. The trial was registered on the clinical trials.gov database (Identifier NCT 01448902). Results: During the first treatment period, treatment with OC 000459 significantly reduced both nasal and ocular symptoms in allergic subjects compared with placebo after challenge with grass pollen. A significant effect was observed on the 2nd day of dosing which was increased on the 8th day of dosing. The therapeutic effects of OC 000459 persisted into the second treatment period despite a 3‐week washout phase. The safety profile of OC 000459 was similar to that of placebo. Conclusion: Treatment with OC 000459 was well tolerated and led to a significant and persistent reduction in the symptoms of rhinoconjunctivitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802155792 · Cited by 35
Self-citation
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Richard, C., Wadowski, M., Goruk, S., Cameron, L., Sharma, A. M., & Field, C. J. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000379 · Cited by 170
“Finally, it would have been important to document the duration of the obesity and/or type 2 diabetes conditions in these participants to determine if the time of exposure has an impact on the differences observed in immunological variables.”
BackgroundLipid mediators and allergic diseases
Fanning, L. B., & Boyce, J. A. (2013) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2013.06.031 · Cited by 70
Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
“Interestingly, two DP2 antagonists, BI 671800 and OC 000459, have shown safety and efficacy in the treating SAR symptoms [120,145].”
Background
Metadata
- Authors
- Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., & Pettipher, R.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2012-10
- Volume
- 67
- Issue
- 12
- Pages
- 1572-1579
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2064998500
- Cited by
- 85
- References
- 1
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.